Non-profit research organisation Biohub has released what it claims is an AI-powered "world model" of protein biology that ...

After its advisory committee voted against AstraZeneca's camizestrant as a treatment for breast cancer in April, the FDA has ...

A $140 million fund has been launched by Coefficient Giving, a health-focused philanthropic organisation, to fund R&D into ...

Roche has introduced what it says is the first comprehensive panel of certified algorithms to help manage people living with ...

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Kris Kaneta, chief product officer at Norstella, which is helping life sciences companies speed up development with instant ...

Big pharma group GSK has been ruling the market for shingles vaccines for many years, but little Dynavax Technologies has aspirations to knock off its crown. The Emeryville, California-based biotech ...

Digital medicine specialist Newel Health has formed an alliance with packaging group Gerresheimer to help pharma companies ...

Nearly two years after Takeda pulled its US marketing application for a vaccine against dengue fever, MSD has advanced a rival shot into phase 3. The international MOBILIZE-1 trial is looking at a ...

Millions of people in the UK will be given the opportunity to take part in clinical trials via the NHS App as part of the government's long-awaited 10-year plan for the health service. According to ...

Around seven years after exiting the infectious disease category, Eli Lilly is back – thanks to a trio of acquisitions worth more than $3.8 billion. At a stroke, the deals to acquire Curevo, LimmaTech ...

Inizio, the leading global commercialization partner to the health and life sciences industry, today announced the launch of ...

Sobi's $1.5 billion takeover of Arthrosi at the end of 2025 has started to pay off, with a positive phase 3 trial for gout ...